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Abstract. Plasma growth hormone (GH) responses to various stimuli were examined in 21 patients with
GH-producing pituitary adenomas, classified into three types by the immunohistochemistry of
cytokeratin and the glycoprotein hormone a-subunit distribution. Seven type I adenomas were
exclusively composed of cells in which the cytokeratin formed a dot-like pattern; they rvere
chromophobic to hematoxylin and eosin (H&E), occasionally positive for GH, and almost completely
negative for the a-subunit. Thirteen type 2 adenomas were composed of cells with cytokeratin that had a
perinuclear distribution; they were eosinophilic to H&E, and diffusely positive for both GH and the
a-subunit. One patient had a type 3 adenoma which had a mixed pattern of intracellular cytokeratin
distribution and was chromophobic and eosinophilic to H&E. Clinically, type I is characterized by earlier
onset, larger tumor size, and more frequent aggressive extension. Paradoxical GH responses to TRH
and OGTT were seen in I of 6 patients (16.7%) of type I and 8 of 9 patients (88.9%) of type 2,and0% of
type I and 62.5% of type 2, respectively. Type 2 cases showed higher plasma GH response to
GH-releasing hormone, and a tendency to greater suppression of plasma GH by bromocriptine
compared with type L Octreotide acetate administration revealed that the nadir,/basal ratio of plasma
GH levels was 42.9+6.6% intype I and 13.5+5.87o in type 2. These results suggest that there is a
pathophysiological difference between these two distinct types of GH-producing pituitary adenomas.
Ke1 uords: Acromegaly, Cytokeratin, Immunohistochemistry, Growth hormone (GH), Somatostatin.
(Endocrinol Japon 39: 355-363, 1992)
SANO el al. recently reported that growth hor-
mone (GH)-producing pituitary adenomas could
be classified into at least two types according to the
intracytoplasmic distribution of immunoreactive
cytokeratin !]. Cytokeratin is considered to have a
certain unknown function within the cells besides
forming their framework. In GH-producing
pituitary adenomas, a distinct distribution of
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cytokeratin has been reported, and a functional
abnormality of these cells has been suggested.
On the other hand, abnormalities of GH secre-
tion in acromegalic patients include a high plasma
GH level, impaired inhibition or paradoxical in-
crease in GH after glucose insestion [2], and
stimulation of GH release by thyrotropin-releasing
hormone (TRH) [3-5], or various GH response to
GH-releasing hormone (GHRH) [6]. Bromocrip-
tine 17, 8] and the somarostarin analogue
octreotide acetate suppress GH release in patients
with acromegaly [9, l0]. However, heterogeneous
responses to these provocative and suppressive
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Table l. Summary of immunohistochemical findings, plasma hormone levels, and radiological staging of patients with
acromegaly
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'fhedegreeof stainingisexpressedasfollows: 
-,nopositivecells; *,occasional; **,frequent; +++,many; ++++,
most cells are positive.
GH, growth hormone; PRL, prolactin; ND, not done.
Dot, cytokeratin was stained in a dotlike pattern; P.D., cytokeratin was stained with perinuclear distribution;
P.D.>>dot, cells with dors were seen in only a few adenoma cells; P.D.<dot, cells with dots were seen more often than
those with perinuclear distribution.
Radiological staging was according to Hardy il81.
agents have been shown and no universal trend
has been established [1]-17].
In the present study, we investigated differences
in pathological findings, clinical features and
plasma GH responses to various loading tests in
patients with GH-producing pituitary adenomas.
Materials and Methods
Patients
Twenty-one patients with acromegaly (Table 1)
were examined before and after transsphenoidal
adenomectomy. The diagnosis of acromegaly was
made on the basis of clinical and endocrinological
findings, and the adenoma tissues were obtained at
surgery for light microscopic and immunohis-
tochemical studies. The study was approved by the
Human Subjects Protection Committee, School of
Medicine, University of Tokushima, and informed
consent was obtained from all patients.
Plasma leuels of GH and prolactin
Plasma levels of GH and prolactin (PRL) before
and after provocative and suppression tests were
determined by radioimmunoassay (RIA).
Blood samples were taken from the antecubital
vein between 0800 and 0900 h after an overnight
fast for measurement of basal plasma levels.
Evaluations were made on at least 3 separate days
and the average value was calculated. Plasma GH
response to 500 g.g TRH (Takeda Pharma-
coceutical Co., Ltd., Osaka, Japan) and 100 pr.g
GHRH (Sumitomo Pharmacoceutical Co., Ltd.,
Tokyo, Japan) given iv for l5 s was studied at 0,
15, 30, 60, 90 and 120 min after the injection. GH
response to oral administration of 75 g glucose was
studied at 0,30,60,90, 120 and 180 min after.
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Response to bromocriptine (2.5 mg po; Parlodel@,
Sankyo Pharmacoceutical Co., Ltd., Tokyo, Japan)
or octreotide acetate (50 pcg sc; Sandostatin,
Sumitomo Pharmacoceutical Co., Ltd.) was stu-
died 0, l, 2, 4,6 and 8 h after treatment. These
tests were performed from 0800-0900 h on
separate days.
Hormone assay
The plasma GH level was measured with a
GH-IRMA kit (Daiichi Radioisotope, Tokyo,
Japan). The sensitivity was 0.05 ng/ml and the
within-assay coefficient of variation was less than
7Vo. The plasma PRL level was measured with a
double-antibody RIA kit supplied by Dainabbot
Co., Ltd. (Osaka, Japan).
Radiologtcal eualuation
Preoperative radiological evaluation included
skull x-ray examination and computed tomogra-
phy, with magnetic resonance imaging (MRI) in
selected patients. Hardy's criteria [8] were used
for radiological classification. In brief, the stage I
tumor was less than 10 mm in diameter and the
stage II tumors greater than l0 mm in diameter;
both were within the sella. Stage III tumors show
signs of localized invasion of the sella, and stage IV
tumors signs of diffuse destruction of the sella.
P athologtcal eualuation
Surgically removed pituitary adenomas were
studied by light microscopy and immunohistoche-
mistry by means of methods described previously
[]. Immunohistochemistry was performed by the
avidin-biotin-peroxidase complex (ABC) method
with an ABC kit (Vector Lab, Burlingame, CA,
USA). The following primary antibodies were
used: anti-human cytokeratin CAM 5.2 (25 y.glml,
Becton-Dickinson, San Jose, CA, USA) which is
specific for cytokeratins 8 and 18, and anti-a-
subunit of monoclonal antibody to the a-subunit
of glycoprotein (l : 1,000, ICN Immunobiologicals,
Lisle, IL, USA). The following primary antisera
were used: anti-GH (l:800, DAKO, Santa Bar-
bara, CA, USA), and anti-PRL (l:2,000, DAKO,
Santa Barbara, CA, USA). Details of the proce-
dure have been described elsewhere by Sano el a/.
tll.
Statistical analysis
Data are expressed as the mean -f SD. Student's
,-test was used to compare plasma hormone levels
in the two groups and analysis of variance was
used to compare the differences at different time
points.
Results
Pathologl of GH-producing pituitary adenoma
GH-producing pituitary adenomas were divided
into type I (7 cases), type 2 (13 cases), and type 3 (l
case) according to the histological and immunohis-
tochemical findings (Table l).
Type I adenomas showed a paranuclear nodu-
lar reaction by cytokeratin staining (Fig. la) and
chromophobic cells with an intracytoplasmic un-
stained nodular (dot-like) area and an irregular
nucleus (Fig. lb) following hematoxylin and eosin
(H&E) staining. The area positive for cytokeratin
was consistently unstained by H&E. Although the
number of GH-immunoreactive cells varied from
case to case, it was generally less in type I than in
type 2 (Fig. lc). The s-subunit was negative in six
of seven cases (Fig. ld).
Type 2 adenomas showed signs of a partial or
complete perinuclear distribution surrounding the
nucleus following cytokeratin staining (Fig. 2a)
and eosinophilic granular cytoplasma and a round
nucleus following H&E staining (FiS. 2b), with no
unstained area of the kind seen in type I adeno-
mas. Immunohistochemical study revealed a lar-
ger number of cells positive fbr GH in all cases
(Fig. 2c), and staining was positive for s-subunit in
ll of 13 cases (Fig. 2d).
Type 3 showed a mixed pattern of intracellular
cytokeratin distribution and was chromophobic
and eosinophilic to H&E stain. Immunohistoche-
mical study revealed the presence of positive cells
for GH and PRL, but no cells reactive for the
s-subunit.
Clinical features of lhe palient.s
Type I included two men and five women, with
an average age of 39.5+4.2 yr. Type 2 included
four men and nine women, with an average age of
47.4+ 14.6 yr.
BANDO′′α′
?
?
?
?
?
??
??
?
?
?
??
??
??
）
?
「
〓
?
?
）
〓
?
?
?
?
?←?
』
?
?
?
?
?
?
?
?
?
?
』
?
?〓
?
?
?
??
?
?
?
?
?
、
〓
?
?
「
?
?
〓
?
?
??
?〓
。
?
?
?
〓
?
?
【?
?
）
?
?
?
?
?
?
?
?
?
、
「
?
?
?
?
?
?
?
?
?
?
?
?
?
?〓
?
?
?
??
?
』
」
??
?
?
??
??
?
?
〓
?
。
?
??
?
??
ョ
?
』
?
【?
?
?
』
』
?
〓
?
?
?
?
?
?
】?
』?
】?
?
?
?
?
?
?
??
???
?
???
?
??
】?
。
????』??
?
?
?
?
??
〓
?〓
。?
?
?
?
?
?
?
?
???
?
?
?
?
?
?
?〓
?）
??
?
?
?
??
?????
?
?
?
〓
〓
】
?
?
?』??
?
????
」。
?
?
?
?
??
???
??
?
【??
?
?』?
?
?
??
?
?
】?
?
?
?
?
??
??
?
』?
〓
?
???
?
?
?、??
」?
?
?』??「
?
。
〓
?。
??
〓
?
?
?
??
?
?
??
?
【?
?
?
??
」?
?
??
?
】?
?
?
?
??
?
』?〓
?
〓
?
?
?
?
???
?
?
』?
?
｝?
?
）
?
?
?
?
】』?
〓
?
〓
??
?
??
〕?
?
??
?
??
?
?
?
??
???
?
??
??
｝】
?
．【
．ぃ
????
?
?
?
?
??
?
?
?
?，
?
??
? .‐‐ ■機
■●|‐
埒
:Ph螂饂
●
1瀑
11購機藪..
∫
(
?〓
?
?
?
，
?
―
?
?
?
?
?
?
?
?
?
?
?
?
．
?
?
?
?
?
?
?
?
?
魃
?
??
?
?
?
||'■
（?
?
GH RESPONSES AND PATHOLOGY IN ACROMECAL■
??
．???
?
*,{s
健
機
0
?
?
?
?
?
?
??
?
??
?
?
?
?
??
?
??
?
??
）
?
?
?
?
?
）
〓
?
ぅ
?
ぅ
?←?
?
?
」
?
?
「
???
?
?
?
?
?
〓
?
?
?
?。
〓
?
」
?
?
?
?
??
?
??
?
（
?
?
?
?
?
。
〓
?
。
??
〓
?
?
?
?
〓
〓
??
】?
?
）
』
?
」
?
?
「
???
?
?
』
?
?〓
?
っ
?
??
〓
?
?
?
?
?
?
??
??
??
?
?
??
?
?
?
?
?
?
』
?
?
?
?
?
ぁ
?
??
?
?、
?
』
?
】?
?
?
』
?
。
〓
】〓
?
?
?
【??
?
?
?
?
〓
?〓
?
?
?
?
?
?
?
?
?
??
?
?
?
。
??
?
?
。
?
?
?
?
?
?
?
?
?
【?
?
?
」』
??
?
。
「
?
?
?
』
?
?
?
?
?
?
?
?
?
【?
?
?
?
』
?
「
?
』
?
〓
?
?、
?
」
?
?
』
??
?
?
?
〓
?
?
??】〓
?
?
?
?
〓
?
】
??
?
?
?
?
?
?
?
」
?
?
??
?
?
?
?
「
?
?
、
』
?
〓
ぅ
〓
?
?
?
?
??
?
?
?
?
?
‐?
?
〔
?
?
?
?
?
?
】』
?
?
?
〓
?
?
?
?
?
」
?
?
??
〓
【?
?
?
?
】?
?
】?
?
??
??
｝
】
?
．?
．?
】』
■
‐          哺議
菫‐了
篠
t‐
 憮
1丞
359
??
?
360
Median basal plasma GH levels in types I and 2
were 59.9 ng/m/ and 33.3 nglml, respectively.
Percentages of cases with plasma GH levels > 40
ng/m/ were 7l7o in type I and 46% in type 2 (no
sienifi cant difference).
Endocrine testing
Plasma GH response to TRH in types I and 2,
expressed by the ratio to the basal plasma GH
level, is shown in Fig. 3a. In type I the peak/basal
ratio was never more than 2, whereas in type 2 it
was more than 2 in g0% of the patients (significant
difference, P<0.01).
Plasma GH response ratio for GHRH is shown
in Fig. 3b. A peak/basal ratio of more than 2 was
07o in type 1, and 80% in type 2 (significant
difference, P<0.01).
Plasma GH response to 75 g oral glucose
tolerance test (OGT f) is shown in Fig. 3c. No type
I patients had a paradoxical GH rise (peak/basal
ratio of plasma GH level being more than 2). In
contrast, five of eight type 2 patients had a
paradoxical GH rise.
lうANDO´′″/
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Fig. 3. Plastna grorvth hornrone (GH) responses to thyrotropin-releasing hormone (-fRH) (500 pg, iv),
GH-releasine hormoltc (C,HRH) (100 pg, iv), and gltrcose (75 g, po) in patients with GH-producing
pituitary adenoma classified as types I and 2. The upper ancl lower panels represent the responses ir rypes
I and 2, respectively. 'l-he case number is indicated in the ligure.
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Plasma GH response to bromocriptine is shown
in Fig. 4a. The average suppression rate at 4 h was
62.4+24.1% in type I and 44.8+32.4% in type 2,
(not significant).
The plasma GH response to octreotide acetate is
shown in Fig. 4b. The nadir/basal ratio was
42.9+6.6Vo in type 1 and 13.5+5.8Vo in type 2
(P<0.001). In type 2, the plasma GH level was
suppressed to 15.2+5.4Vo of the basal level 2 h
after the administration.
Radiological euaLuation
Lesions graded as III and IV were seen in 86%
of patients classified as type l, and in only 3l% of
type 2 (P<0.01) (Table 1).
Discussion
GH-producing pituitary adenoma can be clas-
sified grossly into two types based according to the
distribution patterns of cytokeratin and GH by
means of light microscopy and immunohistoche-
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mistry []. In this study, we investigated the
differences in clinical and endocrinological aspects
of the two types in patients with GH-producing
pituitary adenoma by performing provocative and
suppressive tests.
The 2l patients were divided into three types
according to the immunohistochemical patterns of
cytokeratin (especially), GH, and the s-subunit.
The protein cytokeratin makes up the cytoskeleton
of cells and sometimes forms fibrous bodies
!9-2 l] that are rarely seen in normal pituitary
cells, but are frequently observed in GH-
producing pituitary adenomas; this finding sug-
gests a functional abnormality of GH-producing
pituitary adenomas.
Oornpared u'ith the classificati<ln b1' Kovacs and
Hon'ath [22], t,vpe I corresponded rnainh' to
sparsell' p;ranulatecl somatotrophic adenorna, in-
cludir-rs acidophil stem cell aclenoma ancl mixed
sparseh' GH-PRL cell adenoma. Tvpe 2 seerns to
corresponcl rnainlv to densell' sranulated s()tllato-
trclphic adenoma, including mantmos()lttato-
trophic cell adenonra and mixed denselv sranu-
lated ()H-PRL cell adenoma. -fype 3 ntav corres-
4
Time(hr)
pond to mixed GH-PRL cell adenoma and to other
types [, 23, 24,25]. These different cell types
seem to reflect pathophysiological as well as histo-
logical differences.
When the clinical features of the patients were
evaluated, those with type I disease tended to be
younger and to have a lesion frequently involving
the sella turcica, but those with type 2 tended to be
older and often had microadenoma.
Plasma GH responses to TRH and GHRH were
lower in type I than in type 2 cases. Glucose
administration induced lower plasma GH levels in
type I than in type 2. Plasma GH levels in type I
were not as suppressed as in type 2 after the
administration of bromocriptine or octreotide.
Although there have been many reports on GH
responses to provocative and suppressive agents in
acromegalic patients, our results clearly shou, that
the adenoma cells of type I and type 2 respond
differently to these agents [2-16, 26].
The data suggest that pituitary adenomas of the
two types have different abilities to synthesize and
secrete GH in these loading tests. The reason for
this difference is not yet known, but several
Fig. 4. Plasma growth hormone (GH) responses to bromocriptine (2.5 mg, po) and octreotide acetate (50 pg, sc) in
patients with GH-producing pituitary adenoma classified as types I and 2. The upper and lower panels represent
rhe responses in types I and 2, respectively. The case number is indicated in the figure.
Bromocriptine
361
Octreotide acetate
Octreotide acetate
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mechanisms can be postulated. First, different
cytokeratin distribution may reflect different cellu-
lar dysfunction, resulting in changes in sensitivity
to stimulatory and inhibitory agents. Second, the
characteristics of the receptors to GHRH and
somatostatin might be quite different. In particu-
lar, the difference in GH response to octreotide
suggests that a difference in affinity and the
number of somatostatin receptors may exist
127-291. Third, the amount of production and
secretion of GH per cell in type I is possibly lower
than in type 2, because type I was a larger tumor
and had roughly the same basal GH level as those
of type 2. -I'his may be related to lower ()H
responses to TRH, GHRH, and glucose in type l.
Out typing of GH-producing pituitary adeno-
mas seems to be useful for following: l) a
classification based on immunohistochemical
findings is technically simpler than that in an
electron microsc<tpic study; 2) plasma GH re-
sponses to various tests enable us to predict to
some degree the immunohistological characteris-
tics of the adenoma; 3) these characteristics would
possibly predict tumor size, aggressive extension,
postoperative recurrence, and ineffectiveness of
brornocriptine and octreotide therapy t30-321.
The differences in cytokeratin distribution might
indicate certain dysfunction of the tumor cells, but
this remains to be investigated in the future.
In summary, GH-producing pituitary adenoma
can be classified into two main types based on the
cytokeratin immunohistochemistry; different cli-
nical features and GH responses are observed.
These findings provide data on the efEcacy of
treatment and prognosis in patients with GH-
producing pituitary adenoma.
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